Meridian Clinical Research, a leading multi-specialty investigative research network, has opened a new standalone research site in Grand Island, NE. The site is located at 3537 West 13th Street, Suite 100, Grand Island, NE 68803.
Local physicians, Adam Brosz, MD, and Erica Haake, MD, will continue to serve as principal investigators and oversee clinical trials at Meridian. Last year, Dr. Brosz oversaw COVID-19 vaccine studies at Meridian, and was a leading enroller for a Phase 3 study of one of the vaccines that has been granted emergency use authorization.
Meridian was founded in Omaha in 1999, and has been longtime leader in vaccine clinical trials. Since the COVID-19 pandemic began, Meridian has enrolled more than 6,000 people into COVID-19 vaccine clinical trials, including the first patients in Phase 2 and 3 trials in the U.S.
The work on COVID-19 vaccines will continue at Meridian’s new site in Grand Island. Dr. Brosz and Dr. Haake are overseeing studies to assess the safety and efficacy of COVID-19 vaccines in children, teens, and pregnant women. All of these studies are held to standards set by the U.S. Food and Drug Administration (FDA), and the data will help determine whether the vaccines can be offered to a broader population.
“We’re proud to expand our footprint in Grand Island and bring more clinical research opportunities to Nebraskans. The community has shown tremendous support for research,” said Nicole Osborn, Founder and CEO of Meridian. “We began our first studies in Grand Island last year just as the pandemic swept across the nation. Principal investigators like Dr. Brosz and Dr. Haake – and trial participants at sites like ours in Grand Island – made it possible to research and develop COVID-19 vaccines that are saving lives right now. The new space reflects our commitment to supporting more clinical trials, jobs, and sustainable growth locally.”
Meridian was founded in Omaha in 1999, and has enrolled more than 50,000 participants into clinical trials. The company’s Grand Island and Hastings sites are now enrolling participants for clinical trials, including COVID-19 vaccine studies.
ABOUT MERIDIAN CLINICAL RESEARCH
Meridian Clinical Research Meridian partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, and diagnostics that could improve human health and wellbeing. Founded in 1999, Meridian is a multi-specialty site network headquartered at its dedicated research center in Omaha, NE, and conducts Phase 1-4 studies at investigative sites nationwide. Meridian supports research across numerous therapeutic areas and excels in high-volume vaccine trials. For more information, visit mcrmed.com.
Meridian Clinical Research